DiaMedica to Present Early Phase 2 Data for DM199 in Fetal Growth…

Event summary

DiaMedica will host a KOL webinar on October 23, 2026, to discuss early Phase 2 results for DM199 in fetal growth restriction (FGR).
First cohort of six participants completed dosing at 5 µg/kg; second cohort dosing at 10 µg/kg has begun.
Interim topline results from the first cohort will be presented by Professor Catherine Cluver, the trial's Principal Investigator.
Panel includes leading maternal-fetal medicine specialists from Stellenbosch University, University of Melbourne, and King’s College London.

The big picture

DiaMedica’s focus on fetal growth restriction with DM199 aligns with the broader industry push for novel therapies in high-risk pregnancy complications. The Phase 2 trial results could position DM199 as a potential first-in-class treatment, addressing a significant unmet need in maternal-fetal medicine. Success in this area would not only expand DiaMedica’s pipeline but also strengthen its position in the competitive landscape of vascular and ischemic disease treatments.

What we're watching

Clinical Efficacy: How the interim results from the first cohort will influence the design and expectations for subsequent cohorts in the Phase 2 trial.
Regulatory Pathway: Whether the early data will accelerate DiaMedica’s discussions with regulatory agencies for future trials in FGR.
Market Differentiation: The pace at which DM199 can establish itself as a viable treatment option in the FGR space, given the current lack of approved therapies.